Nahyoung Lee, MD
Ophthalmology · Boston, MANPI 1386898898
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,800 of the $5,198 with a category attached, or 73.1%. 5 manufacturers reported payments, led by Amgen at 58.0% of the total. Reporting peaked in 2024 at $4,056 and has fallen 86.4% since, to $552 in 2025.
Across 33 payments — averaging $157.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3K
- Argenx US, Inc.$2K
- Biotissue Holdings Inc.$188
- Bausch & Lomb Americas Inc.$129
- Boehringer Ingelheim$64
Across 8 payments — averaging $14,552 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$116K
What the payments were for
- Consulting fees$3,80073%
- Travel & lodging$230%
- Food & beverage$1,34126%
- Education$341%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 29 | $3,017 |
| Argenx US, Inc. | 1 | $1,800 |
| Biotissue Holdings Inc. | 1 | $188 |
| Bausch & Lomb Americas Inc. | 1 | $129 |
| Boehringer Ingelheim | 1 | $64 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,198 in reported general payments places this provider in the 80th percentile of 653 ophthalmology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErythromycinErythromycin Base | 30 | $387 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 14 | $178 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Boston
- Rishi SinghBoston$1.7M
- Adam RogersBoston$316K
- Bonnie HendersonBoston$279K
- Dean EliottBoston$250K
- Mina FarahaniBoston$227K
- Jia YinBoston$173K
- John MillerBoston$106K
- Elizabeth RossinBoston$101K
- Suzanne FreitagBoston$96K
- Nimesh PatelBoston$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.